Data gathered: December 22
Alternative Data for Cassava Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 159,000 | Sign up | Sign up | Sign up |
| Google Trends | 3 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 22 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 54,711 | Sign up | Sign up | Sign up |
| Twitter Mentions | 31 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 37 | Sign up | Sign up | Sign up |
About Cassava Sciences
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
| Price | $2.35 |
| Target Price | Sign up |
| Volume | 3,190,000 |
| Market Cap | $113M |
| Year Range | $2.29 - $35.08 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Faruqi & Faruqi Reminds Cassava Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVADecember 22 - Investing.com |
|
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVADecember 21 - Investing.com |
 |
Wellington Management Group LLP Acquires New Holdings in Cassava Sciences, Inc. (NASDAQ:SAVA)December 21 - ETF Daily News |
|
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVADecember 20 - Investing.com |
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitDecember 20 - GlobeNewswire |
|
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVADecember 20 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 13M | -13M | -28M | -31M | -0.580 |
| Q2 '24 | 0 | 46M | -46M | 6.2M | -61M | 0.130 |
| Q1 '24 | 0 | 3.8M | -3.8M | 25M | -20M | 0.580 |
| Q4 '23 | 2.3M | 4.1M | -4.1M | -21M | -23M | -0.500 |
| Q3 '23 | 0 | 4.4M | -4.4M | -26M | -28M | -0.610 |
Insider Transactions View All
| Schoen Eric filed to sell 11,500 shares at $3.9. December 3 '24 |
| ROBERTSON SANFORD filed to buy 886,851 shares at $17.5. August 24 '23 |
| Barry Richard filed to buy 293,477 shares at $16.7. August 23 '23 |
Similar companies
Read more about Cassava Sciences (SAVA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Cassava Sciences?
The Market Cap of Cassava Sciences is $113M.
What is the current stock price of Cassava Sciences?
Currently, the price of one share of Cassava Sciences stock is $2.35.
How can I analyze the SAVA stock price chart for investment decisions?
The SAVA stock price chart above provides a comprehensive visual representation of Cassava Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cassava Sciences shares. Our platform offers an up-to-date SAVA stock price chart, along with technical data analysis and alternative data insights.
Does SAVA offer dividends to its shareholders?
As of our latest update, Cassava Sciences (SAVA) does not offer dividends to its shareholders. Investors interested in Cassava Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cassava Sciences?
Some of the similar stocks of Cassava Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.